Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
7 Odd Apparatuses to Make Your Party Stick Out! - 2Top 20 Compelling Business Books for Progress
- 3An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- 4Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- 5Discovery off Israel’s coast reveals earliest known 2,600-year-old shipment of raw iron
- Vote in favor of your Favored kind of footwear
- New dinosaur tracks in Italy illustrate herds moving in unison
- Palestine weekly wrap: Protests sweep West Bank after death penalty law
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
- Brazil's Bolsonaro to continue his sentence at home because of poor health
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- Well informed: How to Take full advantage of Your Gadgets
- Mobility exercises are an important part of fitness as we age. Here are some tips
